Please login to the form below

Not currently logged in
Email:
Password:

Convergence and Selcia enter collaboration

Newly launched biotech, Convergence Pharmaceuticals, and contract research organisation, Selcia, have entered into a collaboration aiming to discover molecules to treat chronic pain
Convergence Pharmaceuticals, a UK-based pharmaceutical company recently launched out of GlaxoSmithKline (GSK), and Selcia, a contract research organisation, have entered into a drug discovery collaboration aiming to identify and develop compounds for the treatment of chronic pain. 

Under the terms of the agreement, Convergence Pharmaceuticals will apply its ion channel biology platform, medicinal chemistry know-how and preclinical development expertise to Selcia's medicinal chemistry and chemistry support services. Financial terms were not disclosed. 

Commenting on the announcement, Dr Ged Giblin, head of chemistry and preclinical development at Convergence Pharmaceuticals, said: "We believe the combination of Convergence's platform and Selcia's bespoke approach will provide an innovative model for this drug discovery partnership in finding solutions for a major unmet clinical need."

In the UK alone, four out of five initial visits to the general practitioner (GP) involve pain as the primary symptom, and prescription rates for analgesic medications are the second highest. By 2023 the chronic pain market in the seven major pharmaceutical markets is predicted to reach over $47bn. In the same seven pharmaceutical markets, 160 million people are estimated to suffer from osteoarthritis, 36 million people from chronic lower back pain and sciatica and over 10 million from neuropathic (or nerve) pain.

23rd November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics